172 related articles for article (PubMed ID: 23528442)
1. Current status of the Matson Evaluation of Drug Side Effects (MEDS).
Matson JL; Cervantes PE
Res Dev Disabil; 2013 May; 34(5):1849-53. PubMed ID: 23528442
[TBL] [Abstract][Full Text] [Related]
2. Reliability of the Matson Evaluation of Drug Side Effects Scale (MEDS).
Matson JL; Mayville EA; Bielecki J; Barnes WH; Bamburg JW; Baglio CS
Res Dev Disabil; 1998; 19(6):501-6. PubMed ID: 9836321
[TBL] [Abstract][Full Text] [Related]
3. The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).
Matson JL; Fodstad JC; Rivet TT
J Intellect Dev Disabil; 2008 Dec; 33(4):337-44. PubMed ID: 19039694
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic drug side effects for persons with intellectual disability.
Matson JL; Mahan S
Res Dev Disabil; 2010; 31(6):1570-6. PubMed ID: 20580203
[TBL] [Abstract][Full Text] [Related]
5. An Examination of Psychotropic Medication Side Effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID?
Mahan S; Holloway J; Bamburg JW; Hess JA; Fodstad JC; Matson JL
Res Dev Disabil; 2010; 31(6):1561-9. PubMed ID: 20542660
[TBL] [Abstract][Full Text] [Related]
6. Tardive dyskinesia and intellectual disability: an examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use.
Fodstad JC; Bamburg JW; Matson JL; Mahan S; Hess JA; Neal D; Holloway J
Res Dev Disabil; 2010; 31(3):750-9. PubMed ID: 20207106
[TBL] [Abstract][Full Text] [Related]
7. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs.
Scheifes A; Walraven S; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
Res Dev Disabil; 2016; 49-50():13-21. PubMed ID: 26647003
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use.
Matson JL; Fodstad JC; Neal D; Dempsey T; Rivet TT
Res Dev Disabil; 2010; 31(1):108-16. PubMed ID: 19720497
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability.
Scheifes A; de Jong D; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
Res Dev Disabil; 2013 Oct; 34(10):3159-67. PubMed ID: 23886758
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Drug-Associated Extrapyramidal Symptoms in People With Intellectual Disability: A Comparison of an Informant-Based Scale With Clinical Rating Scales.
de Kuijper GM; Hoekstra PJ
J Clin Psychopharmacol; 2016 Oct; 36(5):508-12. PubMed ID: 27529770
[TBL] [Abstract][Full Text] [Related]
11. Measurement of problem behaviour during medication evaluations.
Zarcone J; Napolitano D; Valdovinos M
J Intellect Disabil Res; 2008 Dec; 52(12):1015-28. PubMed ID: 18717764
[TBL] [Abstract][Full Text] [Related]
12. Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation.
Advokat CD; Mayville EA; Matson JL
Res Dev Disabil; 2000; 21(1):75-84. PubMed ID: 10750167
[TBL] [Abstract][Full Text] [Related]
13. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.
Curran S; Turner D; Musa S; Wattis J
Int J Geriatr Psychiatry; 2005 Sep; 20(9):842-7. PubMed ID: 16116576
[TBL] [Abstract][Full Text] [Related]
14. Cardiac side effects of psychiatric drugs.
Mackin P
Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():3-14. PubMed ID: 18098218
[TBL] [Abstract][Full Text] [Related]
15. Akathisia in adults with severe and profound intellectual disability: a psychometric study of the MEDS and ARMS.
Garcia MJ; Matson JL
J Intellect Dev Disabil; 2008 Jun; 33(2):171-6. PubMed ID: 18569404
[TBL] [Abstract][Full Text] [Related]
16. The overweight: obesity and plasma lipids in adults with intellectual disability and mental illness.
Gazizova D; Puri BK; Singh I; Dhaliwal R
J Intellect Disabil Res; 2012 Sep; 56(9):895-901. PubMed ID: 21883600
[TBL] [Abstract][Full Text] [Related]
17. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices.
Holden B; Gitlesen JP
Res Dev Disabil; 2004; 25(6):509-21. PubMed ID: 15541629
[TBL] [Abstract][Full Text] [Related]
18. [Somatic side effects of psychopharmaceuticals].
Schmidmeier R
MMW Fortschr Med; 2006 Nov; 148(46):27-9. PubMed ID: 17615784
[TBL] [Abstract][Full Text] [Related]
19. [Side effects or predictor of the therapy success? Psychotropic drugs as fattener].
MMW Fortschr Med; 2004 Jan; 146(1-2):8. PubMed ID: 18441570
[No Abstract] [Full Text] [Related]
20. Brief report: reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation.
Schroeder SR; Rojahn J; Reese RM
J Autism Dev Disord; 1997 Feb; 27(1):89-102. PubMed ID: 9018584
[No Abstract] [Full Text] [Related]
[Next] [New Search]
